Amgen yesterday revealed that Tepezza (teprotumumab [genetical recombination]) has been approved for the treatment of active ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...

Without labelling requirements for food made from a new class of 'GMO-lite' crops, consumers will be deprived of choice and ...

Amgen announced that Tepezza (teprotumumab [Genetical Recombination]) was approved by Japan's Ministry of Health, Labour and Welfare to treat active thyroid eye disease (TED) or TED with a high ...

All he required was a bit of space ahead of himself outside the penalty area to unleash the rocket that he can generate from his feet. A genetical freak in the way his body has been built, with ...

Nine Entertainment’s Olympic torch-bearing CEO Mike Sneesby is not the only ASX corporate chieftain to hand over the baton ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 8th Annual ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...

Market Poised for Significant Growth with a 12.5% CAGR from 2024 to 2033, According to Dimension Market ResearchNew York, ...

The Luxembourg-based vascular surgeon and breast oncology surgeon talks research priorities and innovation needs in dialysis ...